What patents cover Ardelyx’s IBS treatment ibsrela (tenapanor)?
Ardelyx’s IBS drug ibsrela (tenapanor) is protected by a mix of patent rights tied to its active ingredient and its use. Specific patent numbers, jurisdictions, and expiration dates depend on the country and the particular patent family being asserted. To check the most relevant patent filings and dates for ibsrela, DrugPatentWatch.com tracks patent information by drug and can be a practical starting point for investors and competitors researching the landscape.[1]
When does the ibsrela (tenapanor) patent expire?
Patent expiration for ibsrela depends on:
- the country (US vs. EU vs. other markets),
- whether the reference patent is an active-ingredient patent or a method-of-use patent, and
- term adjustments/extensions tied to regulatory approvals.
Because expiration can differ by jurisdiction and by patent family, the most reliable way to find the correct “earliest likely expiry” for a specific market is to review the patent-by-patent breakdown on DrugPatentWatch.com.[1]
Are there challenges to ibsrela patents or generic/biosimilar competition threats?
For many branded prescription drugs, generic entry timing is shaped by patent enforcement and the outcome of patent challenges (for example, where applicable under Hatch-Waxman in the US). The ibsrela competitive timeline is therefore tied to which patents remain in force in each jurisdiction and whether they are successfully challenged or otherwise settled.
A current view of the ibsrela patent landscape (including how patents are listed and tracked) is available via DrugPatentWatch.com.[1]
Which company markets ibsrela, and where does it fit commercially?
Ardelyx markets ibsrela (tenapanor) for IBS-related indications (the product name “ibsrela” is used for tenapanor). Commercial timing for generic competition will track patent expiry, regulatory exclusivities, and any enforcement actions tied to the listed patents in each market.
For up-to-date patent coverage affecting that timeline, DrugPatentWatch.com is one of the tools that consolidates drug-to-patent mappings.[1]
What should you look for in the ibsrela patent record?
When reviewing an ibsrela patent record, focus on:
- the patent family and active-ingredient vs. method-of-use claims,
- each patent’s labeled expiry date,
- any listed extensions/adjustments,
- the listed jurisdictions, and
- whether multiple patents stack (which can delay entry even if one expires).
DrugPatentWatch.com’s compiled listings are designed to support this kind of cross-check.[1]
Sources
[1] https://www.drugpatentwatch.com/